
Revolutionizing Uveal Melanoma Treatment: SCANDIUM-II Trial Combines Chemotherapy and Immunotherapy for Promising Results
Roger Olofsson Bagge, MD, PhD, recipient of the 2021 AACR-OMF Career Development Award, in honor of Robert C. Allen, MD, shares how the recent SCANDIUM-II clinical trial found that isolated hepatic perfusion with melphalan in combination with immunotherapies, ipilimumab and nivolumab was efficacious in the treatment of patients with liver-dominant metastases of uveal melanoma, but associated with severe adverse events.